Glucocorticoid-induced hyperglycaemia and diabetes: Call for action.
Journal article
Golubic R. et al, (2022), Diabet Med
Nintedanib for treating progressive fibrosing interstitial lung diseases.
Journal article
Adler AI. et al, (2021), Lancet Respir Med
Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study.
Journal article
Bidulka P. et al, (2021), BMJ Open, 11
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
Journal article
Blood Pressure Lowering Treatment Trialists' Collaboration None., (2021), Lancet, 398, 1053 - 1064
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
Journal article
Rahimi K. et al, (2021), The Lancet, 398, 1053 - 1064
Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89.
Journal article
Wamil M. et al, (2021), Diabetes Care, 44, 1877 - 1884
Accurate accounting of caplacizumab cost effectiveness – Authors' reply
Journal article
Hughes M. et al, (2021), The Lancet Haematology, 8
Adjusting for Nonadherence or Stopping Treatments in Randomized Clinical Trials.
Journal article
Adler AI. and Latimer NR., (2021), JAMA, 325, 2110 - 2111
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
Journal article
Adler A. et al, (2021), The Lancet, 397, 1625 - 1636
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
Journal article
Copland E. et al, (2021), Lancet Oncol, 22, 558 - 570
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis.
Journal article
Copland E. et al, (2021), Lancet Oncol, 22, 558 - 570
The STEP 1 trial for weight loss: a step change in treating obesity?
Journal article
Adler AI., (2021), Nature Medicine, 27, 589 - 590
NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction.
Journal article
Adler AI. et al, (2021), Lancet Diabetes Endocrinol
NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpura.
Journal article
Hughes M. et al, (2021), Lancet Haematol, 8, e14 - e15
Impact of a Global Pandemic on Health Technology Assessment.
Journal article
Lorgelly PK. and Adler A., (2020), Appl Health Econ Health Policy, 18, 339 - 343
Cannabidiol with clobazam for seizures associated with Dravet and Lennox-Gastaut syndromes
Journal article
Lamb A. et al, (2020), The Lancet Neurology, 19, 290 - 291
NICE guidance on sotagliflozin for type 1 diabetes.
Journal article
Adler AI. et al, (2020), Lancet Diabetes Endocrinol, 8, 274 - 275
To treat or not to treat: dysglycaemia in cystic fibrosis.
Journal article
Adler AI., (2019), Diabetic medicine : a journal of the British Diabetic Association, 36, 1365 - 1366
NICE guidance on dapagliflozin with insulin for type 1 diabetes.
Journal article
Adler AI. et al, (2019), The lancet. Diabetes & endocrinology, 7, 750 - 751
Ocrelizumab for primary progressive multiple sclerosis.
Journal article
Adler AI. and Knight H., (2019), The Lancet. Neurology, 18, 816 - 817